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Background: The development of behavioral addictions (BAs) in association with dopamine agonists
(DAs, commonly used to treat Parkinson’s disease) has been reported. A recent report presented data that these
associations are evident in the US Food and Drug Administration’s (FDA) Adverse Event Reporting System
(FAERS), a database containing information on adverse drug event and medication error reports submitted to the
FDA. However, given that vulnerability to publicity-stimulated reporting is a potential limitation of spontaneous
reporting systems like the FAERS, the potential impact of publicity on reporting in this case remains unclear.Method
and aims: To investigate the potential impact of publicity on FAERS reporting of BAs in association with DAs
(BAs w/DAs) as presented by Moore, Glenmullen, and Mattison (2014), news stories covering a BA/DA association
were identiﬁed and compared with BA w/DA and other reporting data in the FAERS. Results: Fluctuations in the
growth of BA w/DA reporting to the FAERS between 2003 and 2012 appear to coincide with multiple periods of
intensive media coverage of a BA/DA association, a pattern that is not evident in other reporting data in the FAERS.
Discussion/Conclusions: Publicity may stimulate reporting of adverse events and premature dismissal of the potential
inﬂuence of publicity on reporting may lead to mistaking an increased risk of an adverse event being reported for an
increased risk of an adverse event occurring.
Keywords: behavioral addictions, impulse control disorders, Parkinson’s disease, dopamine agonists, gambling,
FDA Adverse Event Reporting System
INTRODUCTION
The development of behavioral addictions (BAs, also
referred to as impulse control disorders) in association with
dopamine agonists (DAs, commonly used to treat
Parkinson’s disease) has been reported (Dodd et al., 2005;
Driver-Dunckley, Samanta, & Stacy, 2003; Szarfman,
Doraiswamy, Tonning, & Levine, 2006; Weintraub et al.,
2010). Moore et al. (2014) present evidence that these
reported associations are evident in the US Food & Drug
Administration’s (FDA) Adverse Event Reporting System
(FAERS), a database containing information on adverse drug
event (ADE) and medication error reports submitted to the
FDA. Speciﬁcally, Moore et al. (2014) conducted a retro-
spective disproportionality analysis based on the 2.7 million
serious domestic and foreign ADEs reported to the FAERS
from 2003 to 2012. A threshold consisting of a proportional
reporting ratio (PRR) ≥ 2 was used to detect signals (drug-
associated adverse events) involving any of six DAs and any
of 10 terms (or ADEs) in the Medical Dictionary for Regula-
tory Activities characterized as BAs. They identiﬁed 1,580
reports containing at least one BA, 710 of which also con-
tained aDA, and reported a PRR for reports containing both a
BA and a DA (BAs w/DAs) of 277.6 (p < 0.001).
The authors concluded that their ﬁndings conﬁrm
prior reports of a BA/DA association. However, given
three factors, it is possible that their ﬁndings could have
been affected by publicity. First, vulnerability to publicity-
stimulated reporting has been described as a limitation of
spontaneous reporting systems like the FAERS (Bate &
Evans, 2009; Moore et al., 2003). Second, between 2003
and 2012, the development of BAs in association with DAs
received considerable media coverage on multiple occa-
sions. Third, a 2014 research report, which, in its analysis of
FAERS reporting cast a wider net than Moore et al. (2014)
with respect to both number of BAs analyzed (16 versus 10)
and type of report analyzed (both serious and non-serious
reports were included), found no or only very weak associa-
tions prior to publicity between DAs and BAs that could be
grouped under the general headings binge eating, compul-
sive shopping, and hypersexuality (pre-publicity data on
reports of gambling to the FAERS are not freely available)
(Gendreau & Potenza, 2014).
Moore et al. (2014) brieﬂy allude to the issue of publicity
in their discussion and suggest that it cannot account for
their ﬁndings. Speciﬁcally, they characterize growth in BA
w/DA reporting (“dopamine receptor agonists” in Figure 1)
between 2003 and 2012 as steady and conclude that it is
therefore unlikely that a burst of publicity or speciﬁc
events explain their ﬁndings. We contend that growth in
BA w/DA reporting between 2003 and 2012 was not steady,
but rather it ﬂuctuated, with upticks in reporting in 2004
(approximately 133%) and 2011 (approximately 49%), and
a sustained period of growth between 2005 and 2009
(approximately 588%). Given the observations listed in the
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previous paragraph, we hypothesized that these ﬂuctuations
may coincide with publicity.
METHODS
To investigate the possibility that these ﬂuctuations may
coincide with media coverage, we conducted Internet
searches of 16 major US and international English-language
media outlets between 2003 and 2012 for the keywords
Parkinson’s AND gambling. Of the 68 news stories identi-
ﬁed using this strategy, 35 were included. News stories were
excluded if they only brieﬂy mentioned a BA/DA associa-
tion (26 stories); keywords were found among “comments”
on a story (four stories); they were in “question and answer”
or “Dear Doctor” format (two stories); or the webpage or
article was no longer accessible (one story).
Ethics
Both authors have conformed to the highest standards of
ethical conduct in the submission of accurate data, acknowl-
edging the work of others and divulging potential conﬂicts of
interest. As the study involved the use of publicly accessi-
ble, de-identiﬁed data, signed informed consent was not
necessary for this study. Given the use of publicly accessi-
ble, de-identiﬁed data, the study is exempted from IRB
review under code of federal regulations 45 CFR 46.101(b).
RESULTS
Of the 35 included news stories, 15 were precipitated by
scientiﬁc publications (43%); 10 by lawsuits (29%); 7 by
conference presentations (20%); 1 by a change in pharma-
ceutical company advertising (3%); 1 by a patient’s story
(3%); and 1 for which the catalyst was unclear (3%).
Results are summarized in Figure 2. The uptick in BA
w/DA reporting in 2004 seen in Figure 1 follows a news
story in the New York Times in August 2003 (O’Neil,
2003), precipitated by the publication in the same month of
research conducted by Driver-Dunckley et al. (2003). The
uptick in 2011 follows four news stories in January and
February of 2011 triggered by lawsuits, as well as a CBS
news story in June 2010 (Edwards, 2010) precipitated by a
scientiﬁc publication (Weintraub et al., 2010). The approxi-
mately 588% growth in BA w/DA reporting observed
between 2005 and 2009 coincides with the publication of
26 news stories (74% of the 35 news stories included)
between July 2005 and April 2009, most of which were
prompted by scientiﬁc publications (Bostwick, Hecksel,
Stevens, Bower, & Ahlskog, 2009; Dodd et al., 2005;
Szarfman et al., 2006; Voon et al., 2007), conference
presentations, and lawsuits.
DISCUSSION
Upticks in BA w/DA reporting to the FAERS appear to
either follow or coincide with publication of news stories.
Moreover, ﬂuctuations in BA w/DA reporting are not
reﬂected in the trajectories plotted for all FAERS reports
or BA w/non-DA reports (Figure 3), which suggests the
presence of some inﬂuence on the BA w/DA reporting rate
speciﬁcally. That ﬂuctuations in news coverage may coin-
cide with ﬂuctuations in BA w/DA reporting suggests the
possibility that publicity may have inﬂuenced reporting.
Given the possibility that publicity could have inﬂuenced
their ﬁndings, it would have been helpful if Moore et al.
(2014) had provided PRRs for clinically related groupings
of the 10 BAs analyzed. This would make it easier to assess
Figure 1. Trend over time for reports of pathological gambling,
hypersexuality, and related impulse control disorders.
Total domestic and foreign reports of serious injury received by the
US Food and Drug Administration containing any of 10 terms in
the Medical Dictionary for Regulatory Activities that characterize
the impulse control disorder under study. (Reproduced with
permission from the American Medical Association: JAMA
Internal Medicine (Moore et al. (2014); 174(12):1930–1933.)
Copyright © 2014 American Medical Association. All rights
reserved.)
Note: In the current study, impulse control disorders are referred to





















Figure 2. Number of news stories covering a BA/DA association,
2003–2012.
BA = behavioral addiction, DA = dopamine agonist.
Note: News stories data were compiled from Internet searches of
16 major US and international English-language media outlets for
the terms Parkinson’s AND gambling (ABC News, CBS News,
CNBC, CNN, The Globe & Mail, The Guardian, Hufﬁngton Post,
MSNBC, NBC News, The New York Times, NPR, Scientiﬁc
American, Time, USA Today, The Wall Street Journal, and The
Washington Post)
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the degree to which the overall PRR of 277.6 may be driven
by pathological gambling/gambling (two separate ADEs in
the FAERS), which, in 2003, was the ﬁrst BA to be reported
in association with DAs in the mainstream media. Patho-
logical gambling/gambling was also the BA most frequently
reported to the FAERS between 2003 and 2012, accounting
for 42.7% of the 1,902 reports of BAs identiﬁed by
(Moore et al., 2014). It would also have been interesting
to see a comparison between the 2003 PRRs (pre-publicity
for all but pathological gambling) and the 2012 PRRs
(post-publicity for all BAs) for clinically related groupings
of the 10 BAs analyzed.
It should be noted that signiﬁcant complexities exist in
identifying the speciﬁc factors that might cause ADEs and
their reporting. While publicity may inﬂuence reporting, it is
also possible that FAERS reporting may have led to in-
creased publicity, perhaps indirectly through analysis and
reporting of ﬁndings. Possible examples may include
through the FDA’s quarterly reporting of potential drug
safety issues identiﬁed via analysis of FAERS data; updates
to product labeling or product advertising resulting from
analysis of FAERS reporting; or scientiﬁc publication of
analysis of FAERS reporting. Of the 35 news stories
included in the analysis, one cites as its catalyst an update
to possible adverse events listed in a product’s television
advertisements, a change the product manufacturer says was
prompted by a request from the FDA, and two stories cite as
an impetus scientiﬁc publication of analysis of FAERS
reporting. We also note the gradual nature of the sizable
uptick in BA w/DA reporting between 2005 and 2009,
which occurs in the midst of several years of increased
media coverage of a BA/DA association. This ﬁnding would
be consistent with a possible lag, with information taking
time to circulate and lead to reporting, although other
possibilities also exist. It is possible that the BA w/DA
data presented in Figure 1 are inﬂuenced by multiple factors,
some of which are indicated above. While we do not
cover an exhaustive list, the notion that reporting of
BAs in association with DAs might be inﬂuenced by
publicity has important clinical and public health implica-
tions, and is thus not a notion that should be prematurely
dismissed.
CONCLUSIONS
In summary, a BA/DA association has received consider-
able publicity since it was ﬁrst reported in 2003. Data
suggest that publicity may stimulate ADE reporting, and
in this case it may coincide with ﬂuctuations in BA w/DA
reporting. It is important to evaluate the potential effect of
publicity on ADE reporting to guard against mistaking an
increased risk of an ADE being reported for an increased
risk of an ADE occurring (Moore et al., 2003).
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BA w/non-DA Reports All FAERS Reports
Figure 3. Trend over time for BA w/non-DA and all FAERS
reports, 2003–2012.
FAERS = US Food & Drug Administration’s (FDA) Adverse
Event Reporting System, BA = behavioral addiction, DA =
dopamine agonist.
Note: BA w/non-DA reports data were estimated based on data
presented in Moore et al. (2014) (see Figure 1). All FAERS
reports data were obtained from the FDA’s website at http://www.
fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/
Surveillance/AdverseDrugEffects/ucm083765.htm
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